Platelet dysfunction due to renal diseases such as Alport syndrome can be effectively reversed with a successful kidney transplant, according to a study published in the Clinical Kidney Journal.
It is common for patients with end-stage renal disease (ESRD) to experience bleeding, more frequent bleeding into the skin, and bleeding from mucosal surfaces. Several disease-related and external factors are known to contribute to this.
Drugs such as anticoagulant agents used to prevent blood clots from forming during dialysis, gastrointestinal changes, and platelet dysfunction due to increased levels of urea in the blood can predispose patients to bleeding.
Several molecular processes have been identified that promote uremic platelet dysfunction seen in ESRD patients. So far, however, no treatment has been able to effectively improve it, as they can target only one of those processes.
Kidney transplant could be a potential therapeutic option. Since this treatment can reverse the metabolic disarray of ESRD, it could potentially improve — completely or partially — uremic platelet dysfunction.
In the study titled “Successful kidney transplantation normalizes platelet function,” researchers investigated platelet function and the effect of kidney transplants in patients with end-stage renal disease.Share